Overall, the urological device market is very well established. This limits the potential for
substantial growth. Although companies continue to provide novel adaptations for their products,
the general trend within the market is a relatively flat ASP. Additionally, the ASP has been limited
by the lack of reimbursement in some countries and price pressures witnessed across Europe.

The full report suite on the European market for urological devices includes devices for benign prostate hyperplasia (BPH), brachytherapy, urinary catheters, nephrostomy, urinary incontinence, stone management, urological endoscopes and erectile dysfunction (ED).